Visit time | Mean | 95%CIL | 95%CIU | F | P-value |
---|---|---|---|---|---|
2 weeks or 4 weeks | |||||
Low dose group | − 11.4 | − 12.1 | − 10.7 | ||
Medium to high dose group | − 11.3 | − 12.1 | − 10.4 | ||
Higher dose group | − 7.3 | − 10.1 | − 4.5 | ||
Low vs. Medium to high | − 0.1 | − 1.2 | 0.9 | − 0.268 | 0.789 |
Low vs. Higher | − 4.1 | − 7.0 | − 1.2 | − 2.810 | 0.005 |
Medium to high vs. Higher | − 4.0 | − 6.9 | − 1.0 | − 2.663 | 0.008 |
6 weeks or 8 weeks | |||||
Low dose group | − 16.6 | − 17.3 | − 15.9 | ||
Medium to high dose group | − 17.6 | − 18.5 | − 16.7 | ||
Higher dose group | − 12.6 | − 15.6 | − 9.6 | ||
Low vs. Medium to high | 1.0 | − 0.2 | 2.1 | 1.682 | 0.093 |
Low vs. Higher | − 4.0 | − 7.0 | − 0.9 | − 2.521 | 0.012 |
Medium to high vs. Higher | − 5.0 | − 8.1 | − 1.8 | − 3.098 | 0.002 |
12 weeks | |||||
Low dose group | − 20.0 | − 20.8 | − 19.3 | ||
Medium to high dose group | − 21.8 | − 22.8 | − 20.8 | ||
Higher dose group | − 18.2 | − 21.4 | − 15.0 | ||
Low vs. Medium to high | 1.8 | 0.6 | 3.0 | 2.876 | 0.004 |
Low vs. Higher | − 1.8 | − 5.1 | 1.5 | − 1.087 | 0.277 |
Medium to high vs. Higher | − 3.6 | − 6.9 | − 0.3 | − 2.130 | 0.033 |